{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:16:25Z","timestamp":1782407785026,"version":"3.54.5"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","derm.theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.det.2016.11.007","type":"journal-article","created":{"date-parts":[[2017,3,17]],"date-time":"2017-03-17T02:21:34Z","timestamp":1489717294000},"page":"163-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Medical and Maintenance Treatments for Vitiligo"],"prefix":"10.1016","volume":"35","author":[{"given":"Thierry","family":"Passeron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.det.2016.11.007_bib1","doi-asserted-by":"crossref","first-page":"223ra23","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.det.2016.11.007_bib2","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","article-title":"Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy","volume":"151","author":"Craiglow","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.det.2016.11.007_bib3","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jaad.2015.09.073","article-title":"Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)","volume":"74","author":"Harris","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2016.11.007_bib4","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1038\/jid.2015.335","article-title":"Transcriptional analysis of vitiligo skin reveals the alteration of WNT pathway: a promising target for repigmenting vitiligo patients","volume":"135","author":"Regazzetti","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2016.11.007_bib5","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1096\/fj.07-9475com","article-title":"Dickkopf 1 (DKK1) regulates skin pigmentation and thickness by affecting Wnt\/beta-catenin signaling in keratinocytes","volume":"22","author":"Yamaguchi","year":"2008","journal-title":"FASEB J"},{"key":"10.1016\/j.det.2016.11.007_bib6","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1038\/jid.2015.59","article-title":"UV-Induced Wnt7a in the Human Skin Microenvironment Specifies the Fate of Neural Crest-Like Cells via Suppression of Notch","volume":"135","author":"Fukunaga-Kalabis","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2016.11.007_bib7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/bjd.12034","article-title":"Clinical features and histological findings are potential indicators of activity in lesions of common vitiligo","volume":"168","author":"Benzekri","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2016.11.007_bib8","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jaad.2015.05.014","article-title":"Confetti-like depigmentation: A potential sign of rapidly progressing vitiligo","volume":"73","author":"Sosa","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2016.11.007_bib9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000251114","article-title":"Treatment of vitiligo with oral corticosteroids","volume":"153","author":"Imamura","year":"1976","journal-title":"Dermatologica"},{"key":"10.1016\/j.det.2016.11.007_bib10","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1046\/j.1365-4362.1999.00623.x","article-title":"The efficacy of low-dose oral corticosteroids in the treatment of vitiligo patients","volume":"38","author":"Kim","year":"1999","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.det.2016.11.007_bib11","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1046\/j.1365-4362.2000.00006.x","article-title":"Use of high-dose methylprednisolone pulse therapy in patients with progressive and stable vitiligo","volume":"39","author":"Seiter","year":"2000","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.det.2016.11.007_bib12","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1365-4362.1993.tb02754.x","article-title":"Oral mini-pulse therapy with betamethasone in vitiligo patients having extensive or fast-spreading disease","volume":"32","author":"Pasricha","year":"1993","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.det.2016.11.007_bib13","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1067\/mjd.2001.113475","article-title":"Oral dexamethasone pulse treatment for vitiligo","volume":"44","author":"Radakovic-Fijan","year":"2001","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2016.11.007_bib14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2310\/7750.2013.12053","article-title":"Low-dose oral mini-pulse dexamethasone therapy in progressive unstable vitiligo","volume":"17","author":"Kanwar","year":"2013","journal-title":"J\u00a0Cutan Med Surg"},{"key":"10.1016\/j.det.2016.11.007_bib15","first-page":"309","article-title":"Unstable vitiligo responding to methotrexate","volume":"64","author":"Sandra","year":"1998","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.det.2016.11.007_bib16","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jsps.2012.12.003","article-title":"Methotrexate for the treatment of generalized vitiligo","volume":"21","author":"Alghamdi","year":"2013","journal-title":"Saudi Pharm J"},{"key":"10.1016\/j.det.2016.11.007_bib17","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1529-8019.2010.01328.x","article-title":"Oral minocycline in the treatment of vitiligo\u2013a preliminary study","volume":"23","author":"Parsad","year":"2010","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.det.2016.11.007_bib18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4103\/0378-6323.125479","article-title":"Randomized controlled study to evaluate the effectiveness of dexamethasone oral minipulse therapy versus oral minocycline in patients with active vitiligo vulgaris","volume":"80","author":"Singh","year":"2014","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.det.2016.11.007_bib19","doi-asserted-by":"crossref","first-page":"240856","DOI":"10.1155\/2014\/240856","article-title":"Narrow-Band Ultraviolet B versus Oral Minocycline in Treatment of Unstable Vitiligo: A Prospective Comparative Trial","volume":"2014","author":"Siadat","year":"2014","journal-title":"Dermatol Res Pract"},{"key":"10.1016\/j.det.2016.11.007_bib20","first-page":"308","article-title":"Vitiligo and intralesional steroids","volume":"69","author":"Vasistha","year":"1979","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.det.2016.11.007_bib21","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jaad.2014.03.046","article-title":"Intralesional corticosteroid injections for vitiligo: a new therapeutic option","volume":"71","author":"Wang","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2016.11.007_bib22","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1001\/archderm.134.12.1532","article-title":"Nonsurgical repigmentation therapies in vitiligo. Meta-analysis of the literature","volume":"134","author":"Njoo","year":"1998","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.det.2016.11.007_bib23","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/bjd.14356","article-title":"Evidence-Based Management of vitiligo: summary of a Cochrane systematic review","volume":"174","author":"Whitton","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2016.11.007_bib24","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jaad.2008.06.023","article-title":"Therapeutic interventions for vitiligo","volume":"59","author":"Whitton","year":"2008","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2016.11.007_bib25","first-page":"1186","article-title":"Randomized controlled trial comparing the effectiveness of 308-nm excimer laser alone or in combination with topical hydrocortisone 17-butyrate cream in the treatment of vitiligo of the face and neck","volume":"159","author":"Sassi","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2016.11.007_bib26","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1159\/000073099","article-title":"Repigmentation of vitiligo with pimecrolimus cream: a case report","volume":"207","author":"Mayoral","year":"2003","journal-title":"Dermatology"},{"key":"10.1016\/j.det.2016.11.007_bib27","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000065845","article-title":"Repigmentation of vitiligo with topical tacrolimus","volume":"205","author":"Smith","year":"2002","journal-title":"Dermatology (Basel, Switzerland)"},{"key":"10.1016\/j.det.2016.11.007_bib28","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1001\/archderm.139.5.581","article-title":"A\u00a0double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo","volume":"139","author":"Lepe","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2016.11.007_bib29","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1365-2133.2011.10351.x","article-title":"A\u00a0double-blind, randomized, placebo-controlled trial of topical tacrolimus 0.1% vs. clobetasol propionate 0.05% in childhood vitiligo","volume":"165","author":"Ho","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2016.11.007_bib30","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1468-3083.2009.03138.x","article-title":"Response of vitiligo to once- vs. twice-daily topical tacrolimus: a controlled prospective, randomized, observer-blinded trial","volume":"23","author":"Radakovic","year":"2009","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2016.11.007_bib31","first-page":"88","article-title":"Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo","volume":"15","author":"Coskun","year":"2005","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.det.2016.11.007_bib32","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1001\/archderm.142.2.252","article-title":"Lack of efficacy of tacrolimus in the treatment of vitiligo in the absence of UV-B exposure","volume":"142","author":"Ostovari","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2016.11.007_bib33","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1684\/ejd.2009.0779","article-title":"An open randomized study to compare narrow band UVB, topical pimecrolimus and topical tacrolimus in the treatment of vitiligo","volume":"19","author":"Stinco","year":"2009","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.det.2016.11.007_bib34","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1468-3083.2002.00407.x","article-title":"Treatment of vitiligo by topical calcipotriol","volume":"16","author":"Chiaverini","year":"2002","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2016.11.007_bib35","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/j.1468-3083.2008.02839.x","article-title":"A\u00a0double-blind, randomized trial of 0.05% betamethasone vs. topical catalase\/dismutase superoxide in vitiligo","volume":"22","author":"Sanclemente","year":"2008","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2016.11.007_bib36","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","article-title":"Vitiligo","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.det.2016.11.007_bib37","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2133.2012.11197.x","article-title":"Guidelines for the management of vitiligo: the European Dermatology Forum consensus","volume":"168","author":"Taieb","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2016.11.007_bib38","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4103\/0378-6323.90949","article-title":"Segmental vitiligo: a randomized controlled trial to evaluate efficacy and safety of 0.1% tacrolimus ointment vs 0.05% fluticasone propionate cream","volume":"78","author":"Kathuria","year":"2012","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.det.2016.11.007_bib39","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.0906-6705.2006.00413.x","article-title":"Production and clearance of cyclobutane dipyrimidine dimers in UV-irradiated skin pretreated with 1% pimecrolimus or 0.1% triamcinolone acetonide creams in normal and atopic patients","volume":"15","author":"Doelker","year":"2006","journal-title":"Exp Dermatol"},{"issue":"4","key":"10.1016\/j.det.2016.11.007_bib40","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1159\/000088505","article-title":"Topical calcineurin inhibitors decrease the production of UVB-induced thymine dimers from airless mouse epidermis","volume":"211","author":"Tran","year":"2005","journal-title":"Dermatology"},{"key":"10.1016\/j.det.2016.11.007_bib41","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jaad.2006.09.004","article-title":"Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy","volume":"56","author":"Nicolaidou","year":"2007","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2016.11.007_bib42","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2133.2010.10030.x","article-title":"Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials","volume":"164","author":"Schmitt","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2016.11.007_bib43","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/jid.2014.527","article-title":"Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo-controlled study","volume":"135","author":"Cavalie","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2016.11.007_bib44","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1600-0749.1992.tb00562.x","article-title":"Melanocyte-stimulating properties of arachidonic acid metabolites: possible role in postinflammatory pigmentation","volume":"5","author":"Tomita","year":"1992","journal-title":"Pigment Cell Res"},{"key":"10.1016\/j.det.2016.11.007_bib45","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1046\/j.1365-4362.2002.01612.x","article-title":"Topical prostaglandin analog (PGE2) in vitiligo\u2013a preliminary study","volume":"41","author":"Parsad","year":"2002","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.det.2016.11.007_bib46","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2008.08923.x","article-title":"Evaluation of\u00a0safety and efficacy of topical prostaglandin E2 in treatment of vitiligo","volume":"160","author":"Kapoor","year":"2009","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2016.11.007_bib47","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamadermatol.2014.1875","article-title":"Afamelanotide and Narrowband UV-B Phototherapy for the Treatment of Vitiligo: A Randomized Multicenter Trial","volume":"151","author":"Lim","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.det.2016.11.007_bib48","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1001\/jamadermatol.2014.4848","article-title":"Indications and limitations of afamelanotide for treating vitiligo","volume":"151","author":"Passeron","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.det.2016.11.007_bib49","first-page":"343","article-title":"Interfering with the IFN-gamma\/CXCL10 pathway to develop new targeted treatments for vitiligo","volume":"3","author":"Rashighi","year":"2015","journal-title":"Ann Transl Med"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863516301346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863516301346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,4]],"date-time":"2020-10-04T01:09:30Z","timestamp":1601773770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863516301346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0733863516301346"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2016.11.007","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical and Maintenance Treatments for Vitiligo","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2016.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}